The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas
- 17 October 2024
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (38) , 3107-3117
Abstract
Aim: Advances in circulating tumor DNA (ctDNA) analysis for diffuse large B-cell lymphoma (DLBCL) have prompted the evaluation of its utility in other non-Hodgkin lymphomas (NHLs), leading to significant insights into its potential applications.Keywords
Funding Information
- National Natural Science Foundation of China (82300151)
- Xinrui Tumor Support Therapy Project Fund (FB2024012256)
- National Health Commission Medical and Health Science and Technology Development Research Center Post-Marketing Clinical Research Special Project for Innovative Drugs (WKZX2023CX020008)
This publication has 43 references indexed in Scilit:
- High frequency of BCL2 gene rearrangement-negative follicular lymphoma in northwestern ItalyCancer Genetics, 2023
- Global patterns of non‐Hodgkin lymphoma in 2020International Journal of Cancer, 2022
- Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin LymphomasCurrent Treatment Options in Oncology, 2021
- Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA groupHematological Oncology, 2020
- Liquid Biopsy-Based Biomarkers of Treatment Response and ResistanceCancer Cell, 2020
- Oncogenic Signaling Pathways in The Cancer Genome AtlasCell, 2018
- Diffuse large B-cell lymphomaPathology, 2018
- Clinical approach to diffuse large B cell lymphomaBlood Reviews, 2016
- Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphomaCancer, 2015
- Chronic lymphocytic leukemiaCritical Reviews in Oncology/Hematology, 2007